Determination of the anticancer effects of M (Mn, Ni, B) doped ZnO nanoparticles against ovarian and breast cancer cells

Abstract

Breast cancer has the second highest worldwide incidence rate and it has the highest prevalence among the women. Breast cancer, with its high prevalence rates, affects the lives, living standards, and economies of many patients and their families as well as the healthcare services in the public health institutions. The treatment options of the breast cancer depend on the stage of the cancer. Currently, endocrine therapy, radiotherapy, chemotherapy as well as surgery are among the treatment options. Although chemotherapy is widely used against breast cancer, it also brings detrimental side effects alongside to the patients. Therefore, it is imperative and urgent to develop novel therapeutic options against breast cancer. In order to overcome the side effects related with the chemotherapy application, nanomedicine-based agents have gathered an immense attention due to their; enhanced targeting properties, better bioavailability, biocompatibility and multiple functions. ZnO nanoparticles have been in use in cosmetics, dye production and surface modifications of the industrial products. It has also been used in biological and biomedical fields in the recent years. In the light of these, we aimed to find out the possible effects of the anti-proliferative effects of pure, Mn, B and Ni doped ZnO nanoparticles in our project proposal. A 2780 ovarian cancer cell line, ER+ breast cancer cell line (MCF7), ER- breast cancer cell line (MDA-MB-231), and human fibroblast cell line (BJ-5TA). In this way, the appropriate concentration of the most effective nanoparticle type to be used in different cancer types was determined for future experiments on breast cancer and ovarian cancer. In addition, with this study, a preliminary study was obtained in order to see in which cancer type the new drug candidates are more effective, and this study is a preliminary study for further studies of possible drug candidates.